Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Andrea Corona MapLight reports mixed results in Schizophrenia trial In their Phase 2 ZEPHR trial, MapLights novel oral drug for schizophrenia, the Ml/M4 muscarinic agonist ML-007C-MA, successfully hit its primary endpoint but only for the twice-daily version, not the once-daily dose
It provides benzodiazepine-like anxiolytic effects without sedation, cognitive impairment, or dependence risk
If you miss a dose, contact your doctor for instructions
The key is to match the tool to the task
The Pracasil Plus base enhances bioavailability while reducing irritation and occlusion-induced maceration
US$ 29.47
US$ 26.47
US$ 29.78
US$ 23.43
